Catalyst
Slingshot members are tracking this event:
Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADAP |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
T-cell Therapy, Ny-eso Spear, Myxoid Round Cell Liposarcoma
